top of page

Biopharma Daily Stock Updates - 10/06/21

$XBI $122.29 -1.06%

 

Covid Updates

$ENTA +1.1% NEW PRECLINICAL DATA FOR EDP-235, ENANTA’S ORAL PROTEASE INHIBITOR SPECIFICALLY DESIGNED FOR THE TREATMENT OF COVID-19, TO BE PRESENTED AT ISRIV-WHO VIRTUAL 2021 CONFERENCE: COVID-19, INFLUENZA AND RSV: SURVEILLANCE-INFORMED PREVENTION AND TREATMENT source


$VXRT -2.7% Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial source


Pipeline Updates

$BCLI -3.2% BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021 source


$DNLI -0.6% Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS) source


$COCP +0.5% Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza source


$ANIX -2.2% Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology source


$SAVA -8.2% Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease source


$PHAS +10.2% PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021 source


$VIRX -1.4% Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors source


$NTLA -0.0% Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema source


$FDMT +0.9% 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease source


$FDMT +0.9% 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD source


$AVRO +5.1% AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress source


$RDHL -0.2% RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements source


$VYGR +56.7% Voyager Therapeutics Announces License Option Agreement With Pfizer For Next-Generation TRACERᵀᴹ AAV Capsids To Enable Neurologic And Cardiovascular Gene Therapy Programs source



Financial & Business Updates

$FBIO -3.6% Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca source


$PROG +5.2% Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules source


 

Posted by JM

0 comments
bottom of page